263 related articles for article (PubMed ID: 32239385)
61. De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.
Fan Y; Binshen O; Zhang Z; Yi H; Zhang W; Liu Q; Liu Y; Dong L; Wang C
Ann Diagn Pathol; 2022 Jun; 58():151886. PubMed ID: 35255429
[TBL] [Abstract][Full Text] [Related]
62. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
[TBL] [Abstract][Full Text] [Related]
63. The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.
Xu PP; Shen R; Shi ZY; Cheng S; Wang L; Liu Y; Zhang L; Huang R; Ma X; Wu X; Yao H; Yu Y; Zhao WL
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1051-e1058.e1. PubMed ID: 36182550
[TBL] [Abstract][Full Text] [Related]
64. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
Lionakis MS; Dunleavy K; Roschewski M; Widemann BC; Butman JA; Schmitz R; Yang Y; Cole DE; Melani C; Higham CS; Desai JV; Ceribelli M; Chen L; Thomas CJ; Little RF; Gea-Banacloche J; Bhaumik S; Stetler-Stevenson M; Pittaluga S; Jaffe ES; Heiss J; Lucas N; Steinberg SM; Staudt LM; Wilson WH
Cancer Cell; 2017 Jun; 31(6):833-843.e5. PubMed ID: 28552327
[TBL] [Abstract][Full Text] [Related]
65. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.
Takano S; Hattori K; Ishikawa E; Narita Y; Iwadate Y; Yamaguchi F; Nagane M; Akimoto J; Oka H; Tanaka S; Sakata M; Matsuda M; Yamamoto T; Chiba S; Matsumura A
World Neurosurg; 2018 Apr; 112():e69-e73. PubMed ID: 29258950
[TBL] [Abstract][Full Text] [Related]
66. The evaluation of gene mutation profiles by next-generation sequencing in diffuse large B-cell lymphoma.
Özçalımlı A; Erdoğdu İH; Turgutkaya A; Yavaşoğlu İ; Döger FK; Bolaman AZ
Int J Lab Hematol; 2023 Jun; 45(3):310-316. PubMed ID: 36576110
[TBL] [Abstract][Full Text] [Related]
67. Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas.
Tang D; Su W; Wang X; Chu Z; Zhang L; Zhou J; Zhang Q
Brain Tumor Pathol; 2021 Jan; 38(1):50-58. PubMed ID: 33079297
[TBL] [Abstract][Full Text] [Related]
68. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
Pham-Ledard A; Beylot-Barry M; Barbe C; Leduc M; Petrella T; Vergier B; Martinez F; Cappellen D; Merlio JP; Grange F
JAMA Dermatol; 2014 Nov; 150(11):1173-9. PubMed ID: 25055137
[TBL] [Abstract][Full Text] [Related]
69. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.
Castillo JJ; Ghobrial IM; Treon SP
Leuk Lymphoma; 2016 Nov; 57(11):2699-701. PubMed ID: 26980069
[No Abstract] [Full Text] [Related]
70. Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant
Deng AL; Kim YR; Lichtenstein EA; O'Connor OA; Deng C
Haematologica; 2017 Jul; 102(7):e275-e277. PubMed ID: 28341730
[No Abstract] [Full Text] [Related]
71. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
[TBL] [Abstract][Full Text] [Related]
72. Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?
Boiza-Sánchez M; Manso R; Balagué O; Chamizo C; Askari E; Salgado RN; Blas-López C; Aguirregoicoa-García E; Menárguez J; Santonja C; Adrados M; Limeres-González MÁ; Piris MÁ; Rodríguez-Pinilla SM
PLoS One; 2020; 15(11):e0241634. PubMed ID: 33180881
[TBL] [Abstract][Full Text] [Related]
73. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
[TBL] [Abstract][Full Text] [Related]
74. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
[TBL] [Abstract][Full Text] [Related]
75. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
Munshi M; Liu X; Chen JG; Xu L; Tsakmaklis N; Demos MG; Kofides A; Guerrera ML; Jimenez C; Chan GG; Hunter ZR; Palomba ML; Argyropoulos KV; Meid K; Keezer A; Gustine J; Dubeau T; Castillo JJ; Patterson CJ; Wang J; Buhrlage SJ; Gray NS; Treon SP; Yang G
Blood Cancer J; 2020 Jan; 10(1):12. PubMed ID: 32005797
[TBL] [Abstract][Full Text] [Related]
76. Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features.
Li M; Liu Y; Wang Y; Chen G; Chen Q; Xiao H; Liu F; Qi C; Yu Z; Li X; Fan L; Guo Y; Yan Q; Guo S; Wang Z
Am J Surg Pathol; 2017 Oct; 41(10):1322-1332. PubMed ID: 28319526
[TBL] [Abstract][Full Text] [Related]
77. Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.
Choi J; Phelan JD; Wright GW; Häupl B; Huang DW; Shaffer AL; Young RM; Wang Z; Zhao H; Yu X; Oellerich T; Staudt LM
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6092-6102. PubMed ID: 32127472
[TBL] [Abstract][Full Text] [Related]
78. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
[TBL] [Abstract][Full Text] [Related]
79. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
Hunter ZR; Xu L; Tsakmaklis N; Demos MG; Kofides A; Jimenez C; Chan GG; Chen J; Liu X; Munshi M; Gustine J; Meid K; Patterson CJ; Yang G; Dubeau T; Samur MK; Castillo JJ; Anderson KC; Munshi NC; Treon SP
Blood Adv; 2018 Nov; 2(21):2937-2946. PubMed ID: 30401751
[TBL] [Abstract][Full Text] [Related]
80. [CD5- and CD10-positive MYC and BCL2 double-expressor diffuse large B-cell lymphoma with MYD88
Sasaki Y; Murai S; Okamura R; Uesugi Y; Shimada S; Watanuki M; Fujiwara S; Kawaguchi Y; Arai N; Yanagisawa K; Honma M; Yamochi T; Hattori N
Rinsho Ketsueki; 2023; 64(1):42-48. PubMed ID: 36775306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]